Acrongenomics Retains KGMC Group
News Nov 10, 2005
KGMC Group LLC will work with Acrongenomics to complete formal validations of the advanced Nano-JETA™ platform, secure publications of this technology in respected medical and scientific journals and identify ideal partners to commercialize the technology.
“Following a year of thorough study, our scientists and Board of Directors have confirmed that Acrongenomics' know-how in nanotechnology has resulted in compelling breakthroughs, significantly impacting our battle with various diseases such as cancer,” Says KGMC Group President Bill Kanatas.
“We are convinced that Nano-JETA™ technology platform can accelerate and enhance the commonly used Real Time PCR amplification process, so that it is rendered 100% accurate in detecting genetic diseases such as cancer.”
“Neo-EpCAM™ cancer detection assay is the first application utilizing the Nano-JETA™ technology.”
“More so exciting is that the process takes less than two minutes. Because it is fast, inexpensive, easy to administer, non-invasive, accurate, specific and uses existing equipment, we are convinced that the technology will assist physicians in detecting genetic diseases quickly, accurately and early enough to potentially save lives and avoid much cost and anguish.”
“Now confident in the technology, we will assist Acrongenomics in securing a partner to further develop and market such technology.”
New Areas of the Brain Become Active After Students Learn PhysicsNews
Parts of the brain not traditionally associated with learning science become active when people are confronted with solving physics problems.READ MORE
Diamonds Could Decrease Cost of Imaging and Spectroscopy DevicesNews
A new approach shows great promise for enhancing the signal from magnetic resonance imaging (MRI) and nuclear magnetic resonance (NMR) using lasers without expensive magnets.
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE